July 2025 updates to prior authorizations and post-service claim edits

Security Health Plan requires prior authorization (PA) and post-service claim edits (PSCE) on office-administered, medically billed medications to ensure coverage and appropriate payment for those services. The medications listed below will be reviewed for medical necessity by Prime Therapeutics for PA and PSCE starting July 1, 2025:

- denosumab-dssb
- Xbryk® (denosumab-dssb)
- Ospomyv® (denosumab-dssb)
- Stoboclo® (denosumab-bmwo)
- Osenvelt® (denosumab-bmwo)
- tocilizumab-anoh *(IV formulation)*
- Avtozma® (tocilizumab-anoh) *(IV formulation)*
- Datroway® (datopotamab deruxtecan-dlnk)
- Opdivo Qvantig® (nivolumab and hyaluronidase-nvhy)
- Focinvez® (fosaprepitant)
- omalizumab-igec
- Omlyclo® (omalizumab-igec)
- Encelto® (revakinagene taroretcel-lwey)
- Retacrit® (epoetin alfa-epbx)

This list includes the new additions and represents a partial list of the prior authorizations and post-service claim edits required of members and providers to ensure payment for services. Prior authorization will be managed through Security Health Plan's specialty pharmacy medication partner, Prime Therapeutics. Please call 1-800-424-8243 or visit their website for details.

You can review the full list of all medications that require prior authorization and/or post-service claim edit on our website www.securityhealth.org/providers/medical-pharmacy. If you have any questions, please contact Security Health Plan Provider Relations at **1-800-548-1224.**